Xu Y - Search Results

1

Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.

Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H, Lou L. Wang H, et al. Among authors: xu y. Cancer Sci. 2017 Jul;108(7):1458-1468. doi: 10.1111/cas.13253. Epub 2017 May 23. Cancer Sci. 2017. PMID: 28388007 Free PMC article.

2

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.

Quan H, Xu Y, Lou L. Quan H, et al. Among authors: xu y. Int J Cancer. 2008 Apr 15;122(8):1730-7. doi: 10.1002/ijc.23262. Int J Cancer. 2008. PMID: 18074350

3

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. Tian S, et al. Among authors: xu y. Cancer Sci. 2011 Jul;102(7):1374-80. doi: 10.1111/j.1349-7006.2011.01939.x. Epub 2011 May 9. Cancer Sci. 2011. PMID: 21443688 Free PMC article. Clinical Trial.

4

YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance.

Zhao H, Quan H, Xie C, Xu Y, Xie F, Hu Y, Lou L. Zhao H, et al. Among authors: xu y. Cancer Lett. 2012 Jan 1;314(1):54-62. doi: 10.1016/j.canlet.2011.09.013. Epub 2011 Sep 19. Cancer Lett. 2012. PMID: 21982683

5

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.

Zhao J, Quan H, Xu Y, Kong X, Jin L, Lou L. Zhao J, et al. Among authors: xu y. Cancer Sci. 2014 Jan;105(1):117-25. doi: 10.1111/cas.12320. Epub 2014 Jan 4. Cancer Sci. 2014. PMID: 24205792 Free PMC article.

6

Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.

Wang W, Liu Y, Zhao Z, Xie C, Xu Y, Hu Y, Quan H, Lou L. Wang W, et al. Among authors: xu y. Cancer Sci. 2016 Jun;107(6):782-90. doi: 10.1111/cas.12934. Epub 2016 Apr 27. Cancer Sci. 2016. PMID: 27002306 Free PMC article.

7

Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.

Xie C, He Y, Zhen M, Wang Y, Xu Y, Lou L. Xie C, et al. Among authors: xu y. Cancer Sci. 2017 Jul;108(7):1476-1484. doi: 10.1111/cas.13263. Epub 2017 May 23. Cancer Sci. 2017. PMID: 28418085 Free PMC article.

8

SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.

Tong M, Gao M, Xu Y, Fu L, Li Y, Bao X, Fu H, Quan H, Lou L. Tong M, et al. Among authors: xu y. Cancer Sci. 2019 Nov;110(11):3584-3594. doi: 10.1111/cas.14180. Epub 2019 Sep 9. Cancer Sci. 2019. PMID: 31446643 Free PMC article.

9

p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.

Wu Q, Quan H, Xu Y, Li Y, Hu Y, Lou L. Wu Q, et al. Among authors: xu y. J Pharmacol Exp Ther. 2012 Jun;341(3):709-17. doi: 10.1124/jpet.112.191635. Epub 2012 Mar 13. J Pharmacol Exp Ther. 2012. PMID: 22414857

10

(5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition.

Wang L, Xu Y, Fu L, Li Y, Lou L. Wang L, et al. Among authors: xu y. Cancer Lett. 2012 Nov 1;324(1):75-82. doi: 10.1016/j.canlet.2012.05.004. Epub 2012 May 9. Cancer Lett. 2012. PMID: 22579805

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,830 results

Search Page

Filters